Laurence H Klotz

List of Publications by Year
in descending order

418 papers	23,253 citations	14614 66 h-index	9073 144 g-index
460 all docs	460 docs citations	460 times ranked	16803 citing authors

#	Article	IF	Citations
1	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 378, 1767-1777.	13.9	2,036
2	Vitamin E and the Risk of Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1549.	3.8	1,458
3	Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 126-131.	0.8	1,011
4	Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 272-277.	0.8	985
5	A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. European Urology, 2011, 59, 543-552.	0.9	910
6	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. Journal of Urology, 2018, 199, 683-690.	0.2	606
7	A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. European Urology, 2007, 51, 1606-1615.	0.9	572
8	Active Surveillance for Prostate Cancer: A Systematic Review of the Literature. European Urology, 2012, 62, 976-983.	0.9	518
9	The efficacy and safety of degarelix: a 12â€month, comparative, randomized, openâ€label, parallelâ€group phase III study in patients with prostate cancer. BJU International, 2008, 102, 1531-1538.	1.3	516
10	Image-Guided Prostate Biopsy Using Magnetic Resonance Imagingâ€“Derived Targets: A Systematic Review. European Urology, 2013, 63, 125-140.	0.9	479
11	Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. New England Journal of Medicine, 2012, 367, 895-903.	13.9	428
12	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. European Urology, 2013, 64, 544-552.	0.9	383
13	Increasing Hospital Admission Rates for Urological Complications After Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology, 2010, 183, 963-969.	0.2	378
14	Active Surveillance for Prostate Cancer: For Whom?. Journal of Clinical Oncology, 2005, 23, 8165-8169.	0.8	317
15	Feasibility Study: Watchful Waiting For Localized Low To Intermediate Grade Prostate Carcinoma With Selective Delayed Intervention Based On Prostate Specific Antigen, Histological And/Or Clinical Progression. Journal of Urology, 2002, 167, 1664-1669.	0.2	309
16	Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 1998, 338, 1265-1271.	13.9	289
17	Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review. European Urology, 2015, 67, 627-636.	0.9	284
18	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. Journal of Urology, 2018, 199, 990-997.	0.2	279

#	Article	IF	Citations
19	Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. European Urology, 2014, 65, 565-573.	0.9	276
20	Active Surveillance for Prostate Cancer: Progress and Promise. Journal of Clinical Oncology, 2011, 29, 3669-3676.	0.8	264
21	Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Systematic Review of the Literature. European Urology, 2012, 61, 961-971.	0.9	238
22	Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. Journal of Clinical Oncology, 2011, 29, 3443-3449.	0.8	222
23	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer and Prostatic Diseases, 2019, 22, 24-38.	2.0	215
24	Intermittent endocrine therapy for advanced prostate cancer. Cancer, 1986, 58, 2546-2550.	2.0	213
25	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncology, The, 2016, 17, 153-163.	5.1	210
26	Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men. Journal of the National Cancer Institute, 2013, 105, 1050-1058.	3.0	208
27	Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncology, The, 2014, 15, 223-231.	5.1	203
28	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendationsâ€"A Report of a European School of Oncology Task Force. European Urology, 2017, 71, 648-655.	0.9	190
29	Active surveillance for the management of localized prostate cancer: Guideline recommendations. Canadian Urological Association Journal, 2015, 9, 171.	0.3	184
30	Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts. Journal of the National Cancer Institute, 2007, 99, 1793-1800.	3.0	160
31	Impact of Multiparametric Endorectal Coil Prostate Magnetic Resonance Imaging on Disease Reclassification Among Active Surveillance Candidates: A Prospective Cohort Study. Journal of Urology, 2012, 187, 1247-1252.	0.2	157
32	Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. Journal of Urology, 2016, 196, 1651-1658.	0.2	157
33	Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biology and Therapy, 2007, 6, 40-45.	1.5	151
34	Growth Kinetics of Renal Masses: Analysis of a Prospective Cohort of Patients Undergoing Active Surveillance. European Urology, 2011, 59, 863-867.	0.9	143
35	Active surveillance for clinically localized prostate cancerâ€"â€"A systematic review. Journal of Surgical Oncology, 2014, 109, 830-835.	0.8	139
36	Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT. Journal of Clinical Oncology, 2015, 33, 1151-1156.	0.8	139

#	Article	IF	Citations
37	Presurgery Experiences of Prostate Cancer Patients and Their Spouses. Cancer Practice, 1999, 7, 130-135.	0.8	132
38	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	1.2	117
39	Role of â€œsaturation biopsyâ€•in the detection of prostate cancer among difficult diagnostic cases. Urology, 2002, 60, 93-97.	0.5	115
40	Antioxidants Block Prostate Cancer in Lady Transgenic Mice. Cancer Research, 2004, 64, 5891-5896.	0.4	112
41	Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 46-50.	0.8	107
42	Prostate cancer overdiagnosis and overtreatment. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 204-209.	1.2	105
43	Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. European Urology, 2019, 75, 300-309.	0.9	99
44	Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. European Urology, 2020, 77, 311-317.	0.9	99
45	Comparison of Multiparametric Magnetic Resonance Imagingâ€“Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. JAMA Oncology, 2021, 7, 534.	3.4	99
46	Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer. Cancer, 2006, 107, 389-395.	2.0	98
47	Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance. Journal of Urology, 2016, 195, 1409-1414.	0.2	98
48	Survivorship and Improving Quality of Life in Men with Prostate Cancer. European Urology, 2015, 68, 374-383.	0.9	91
49	Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists. European Urology, 2014, 66, 1101-1108.	0.9	90
50	Diet, androgens, oxidative stress and prostate cancer susceptibility. , 1998, 17, 325-330.		88
51	Gonadotropinâ€releasing hormone: An update review of the antagonists versus agonists. International Journal of Urology, 2012, 19, 594-601.	0.5	88
52	Prospective Multi-Institutional Study Evaluating the Performance of Prostate Cancer Risk Calculators. Journal of Clinical Oncology, 2011, 29, 2959-2964.	0.8	86
53	ACTIVE SURVEILLANCE WITH SELECTIVE DELAYED INTERVENTION: USING NATURAL HISTORY TO GUIDE TREATMENT IN GOOD RISK PROSTATE CANCER. Journal of Urology, 2004, 172, S48-50; discussion S50-1.	0.2	85
54	Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology, 2002, 60, 201-208.	0.5	83

#	Article	IF	Citations
55	Modulation of Cell Proliferation and Cell Cycle Regulators by Vitamin E in Human Prostate Carcinoma Cell Lines. Journal of Urology, 2002, 168, 1578-1582.	0.2	82
56	Prostate Cancer Death of Men Treated With Initial Active Surveillance: Clinical and Biochemical Characteristics. Journal of Urology, 2010, 184, 131-135.	0.2	82
57	A prospective comparison of MRIâ€US fused targeted biopsy versus systematic ultrasoundâ€guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. Journal of Magnetic Resonance Imaging, 2015, 41, 220-225.	1.9	82
58	Randomized Clinical Trial of Vitamin D3 Doses on Prostatic Vitamin D Metabolite Levels and Ki67 Labeling in Prostate Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1498-1507.	1.8	81
59	Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. Journal of Urology, 2002, 167, 1664-9.	0.2	80
60	Active Surveillance for Prostate Cancer: A Review. Current Urology Reports, 2010, 11, 165-171.	1.0	77
61	Early experience with intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy. Urology, 1998, 52, 537-542.	0.5	74
62	Active Surveillance with Selective Delayed Intervention Using PSA Doubling Time for Good Risk Prostate Cancer. European Urology, 2005, 47, 16-21.	0.9	73
63	MRI-guided Transurethral Ultrasound Therapy of the Prostate Gland Using Real-time Thermal Mapping: Initial Studies. Urology, 2010, 76, 1506-1511.	0.5	71
64	CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Urology, 1999, 53, 757-763.	0.5	69
65	Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort. Journal of Urology, 2015, 194, 79-84.	0.2	68
66	Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer. Journal of Urology, 2010, 184, 2313-2319.	0.2	67
67	Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Current Treatment Options in Oncology, 2006, 7, 355-362.	1.3	66
68	Locally advanced prostate cancerâ€"biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer, 2007, 109, 858-867.	2.0	66
69	Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback. Physics in Medicine and Biology, 2009, 54, 2615-2633.	1.6	65
70	Semantics in active surveillance for men with localized prostate cancer â€" results of a modified Delphi consensus procedure. Nature Reviews Urology, 2017, 14, 312-322.	1.9	65
71	A Phase 3, Double-blind, Randomised, Parallel-group, Placebo-controlled Study of Oral Weekly Alendronate for the Prevention of Androgen Deprivation Bone Loss in Nonmetastatic Prostate Cancer: The Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) Study. European Urology, 2013, 63, 927-935.	0.9	64
72	Active surveillance for low-risk prostate cancer: an update. Nature Reviews Urology, 2011, 8, 312-320.	1.9	63

#	Article	IF	Citations
73	Surveillance after prostate focal therapy. World Journal of Urology, 2019, 37, 397-407.	1.2	63
74	Urothelial Carcinoma of the Prostate. Urology, 2007, 69, 50-61.	0.5	62
75	A multicenter, randomized, double-blind, placebocontrolled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology, 1996, 47, 335-342.	0.5	61
76	Active surveillance for prostate cancer: trials and tribulations. World Journal of Urology, 2008, 26, 437-442.	1.2	61
77	Cancer overdiagnosis and overtreatment. Current Opinion in Urology, 2012, 22, 203-209.	0.9	61
78	Management of low risk prostate cancerâ€"active surveillance and focal therapy. Nature Reviews Clinical Oncology, 2014, 11, 324-334.	12.5	61
79	A PHASE 1-2 TRIAL OF DIETHYLSTILBESTROL PLUS LOW DOSE WARFARIN IN ADVANCED PROSTATE CARCINOMA. Journal of Urology, 1999, 161, 169-172.	0.2	60
80	Modeling Prostate Specific Antigen Kinetics in Patients on Active Surveillance. Journal of Urology, 2006, 176, 1392-1398.	0.2	60
81	Comparing Prostate Specific Antigen Triggers for Intervention in Men With Stable Prostate Cancer on Active Surveillance. Journal of Urology, 2010, 184, 1942-1946.	0.2	60
82	GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model1Contributed equally and share first authorship.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1126-1134.	0.8	60
83	Active surveillance in intermediateâ€risk prostate cancer. BJU International, 2020, 125, 346-354.	1.3	59
84	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	0.9	58
85	Active Surveillance for Prostate Cancer: Overview and Update. Current Treatment Options in Oncology, 2013, 14, 97-108.	1.3	57
86	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. European Urology, 2014, 66, 619-622.	0.9	57
87	Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. Journal of Urology, 2019, 201, 113-119.	0.2	57
88	Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Research, 2002, 62, 2540-5.	0.4	57
89	Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer. Clinical Cancer Research, 2009, 15, 1787-1793.	3.2	54
90	Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model. Prostate, 2015, 75, 1300-1311.	1.2	54

#	Article	IF	Citations
91	Gonadotropin-Releasing Hormone Blockers and Cardiovascular Disease Risk: Analysis of Prospective Clinical Trials of Degarelix. Journal of Urology, 2011, 186, 1835-1842.	0.2	53
92	The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy. Clinical Cancer Research, 2005, 11, 8391-8397.	3.2	52
93	Intermediate-risk Prostate Cancer: Stratification and Management. European Urology Oncology, 2020, 3, 270-280.	2.6	51
94	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51
95	Prostate cancer screening: Canadian guidelines 2011. Canadian Urological Association Journal, 2011, 5, 235-240.	0.3	50
96	Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix. Urology, 2014, 83, 1122-1128.	0.5	50
97	Cannabinoid WIN 55,212â€2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoidâ€receptor 2 dependent manner. Prostate, 2019, 79, 151-159.	1.2	49
98	Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis. Canadian Urological Association Journal, 2020, 15, E11-E16.	0.3	48
99	Quality of Life, Morbidity, and Mortality Results of a Prospective Phase II Study of Intermittent Androgen Suppression for Men with Evidence of Prostate-Specific Antigen Relapse After Radiation Therapy for Locally Advanced Prostate Cancer. Clinical Genitourinary Cancer, 2008, 6, 46-52.	0.9	46
100	Active surveillance for low-risk prostate cancer. Critical Reviews in Oncology/Hematology, 2013, 85, 295-302.	2.0	46
101	Early Postsurgery Experience of Prostate Cancer Patients and Spouses. Cancer Practice, 2000, 8, 165-171.	0.8	45
102	Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. Journal of Urology, 2021, 205, 769-779.	0.2	45
103	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy NaÃ¯ve Men: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 1085-1093.	0.2	44
104	PSAdynia and other PSA-related syndromes: A new epidemicâ€”A case history and taxonomy. Urology, 1997, 50, 831-832.	0.5	43
105	Maximal androgen blockade for advanced prostate cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 331-340.	2.2	43
106	Appropriateness Criteria for Active Surveillance of Prostate Cancer. Journal of Urology, 2017, 197, 67-74.	0.2	43
107	Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy. Radiology, 2019, 291, 83-89.	3.6	43
108	Active surveillance. Current Opinion in Urology, 2013, 23, 239-244.	0.9	42

#	Article	IF	Citations
109	A Combination of Micronutrients Is Beneficial in Reducing the Incidence of Prostate Cancer and Increasing Survival in theLadyTransgenic Model. Cancer Prevention Research, 2009, 2, 473-483.	0.7	41
110	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	1.4	41
111	Capsaicin: A novel radio-sensitizing agent for prostate cancer. Prostate, 2015, 75, 113-125.	1.2	41
112	Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nature Reviews Urology, 2005, 2, 136-142.	1.4	40
113	Protective effect of metformin in CD1 mice placed on a high carbohydrateâ€“high fat diet. Biochemical and Biophysical Research Communications, 2010, 397, 537-542.	1.0	40
114	Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. Journal of Urology, 2017, 197, 335-341.	0.2	39
115	Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy. Clinical Cancer Research, 2006, 12, 6452-6458.	3.2	38
116	Active Surveillance for Prostate Cancer. JAMA - Journal of the American Medical Association, 2010, 304, 2411.	3.8	37
117	Active surveillance for low-risk prostate cancer. Current Opinion in Urology, 2017, 27, 225-230.	0.9	37
118	Active Surveillance for Low-Risk Prostate Cancer. Current Urology Reports, 2015, 16, 24.	1.0	36
119	Complications After Radical Prostatectomy or Radiotherapy for Prostate Cancer: Results of a Population-based, Propensity Scoreâ€“matched Analysis. Urology, 2015, 85, 621-628.	0.5	34
120	Antiproliferative Mechanisms of the Flavonoids 2,2â€²-Dihydroxychalcone and Fisetin in Human Prostate Cancer Cells. Nutrition and Cancer, 2010, 62, 668-681.	0.9	33
121	The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer. Journal of Urology, 2017, 197, 1068-1075.	0.2	33
122	Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. Journal of Urology, 2018, 199, 147-154.	0.2	33
123	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Annals of Internal Medicine, 2018, 168, 1.	2.0	33
124	Can high resolution micro-ultrasound replace MRI in the diagnosis of prostate cancer?. European Urology Focus, 2020, 6, 419-423.	1.6	33
125	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 343-350.	0.9	33
126	New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biology and Therapy, 2011, 12, 997-1004.	1.5	32

#	Article	IF	Citations
127	Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. Journal of Cancer, 2015, 6, 1160-1171.	1.2	32
128	Contemporary approach to active surveillance for favorable risk prostate cancer. Asian Journal of Urology, 2019, 6, 146-152.	0.5	32
129	Active surveillance for favorable-risk prostate cancer: who, how and why?. Nature Clinical Practice Oncology, 2007, 4, 692-698.	4.3	31
130	The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 81-86.	0.8	31
131	A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies. Radiotherapy and Oncology, 2008, 88, 53-60.	0.3	30
132	Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU International, 2004, 94, 295-298.	1.3	29
133	Combined Androgen Blockade: The Case for Bicalutamide. Clinical Prostate Cancer, 2005, 3, 215-219.	2.1	29
134	Active surveillance for favorable risk prostate cancer: Rationale, risks, and results. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 505-509.	0.8	29
135	Active Surveillance for Favorable-risk Prostate Cancer: Background, Patient Selection, Triggers for Intervention, and Outcomes. Current Urology Reports, 2012, 13, 153-159.	1.0	29
136	Active Surveillance for Intermediate Risk Prostate Cancer. Current Urology Reports, 2017, 18, 80.	1.0	29
137	Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. Nature Reviews Urology, 2020, 17, 469-481.	1.9	29
138	Intraoperative cavernous nerve stimulation during nerve sparing radical prostatectomy: how and when?. Current Opinion in Urology, 2000, 10, 239-243.	0.9	28
139	Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. European Urology, 2017, 71, 534-542.	0.9	28
140	Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference Standard. Journal of Urology, 2017, 197, 255-261.	0.2	28
141	A systematic review of randomized trials in localized prostate cancer. Canadian Journal of Urology, 2004, 11, 2110-7.	0.0	28
142	Laparoscopic retroperitoneal lymphadenectomy for high-risk stage 1 nonseminomatous germ cell tumor: Report of four cases. Urology, 1994, 43, 752-756.	0.5	26
143	Active Surveillance, Quality of Life, and Cancer-related Anxiety. European Urology, 2013, 64, 37-39.	0.9	26
144	MR thermometry in the human prostate gland at 3.0T for transurethral ultrasound therapy. Journal of Magnetic Resonance Imaging, 2013, 38, 1564-1571.	1.9	26

#	Article	IF	Citations
145	World Urologic Oncology Federation Bladder Cancer Prevention Program: A global initiative. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 25-29.	0.8	26
146	Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance. Journal of Urology, 2018, 199, 1475-1481.	0.2	26
147	Active Surveillance for Favorable Risk Prostate Cancer: What Are the Results, and How Safe Is It?. Seminars in Radiation Oncology, 2008, 18, 2-6.	1.0	25
148	Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention. Nature Reviews Urology, 2008, 5, 2-3.	1.4	25
149	Active surveillance. Current Opinion in Urology, 2012, 22, 222-230.	0.9	25
150	Active Surveillance for Low-risk Prostate Cancer: Developments to Date. European Urology, 2015, 67, 646-648.	0.9	25
151	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. European Urology Oncology, 2018, 1, 238-241.	2.6	25
152	Management of low risk prostate cancer. Current Opinion in Urology, 2014, 24, 270-279.	0.9	24
153	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	2.6	24
154	The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. European Urology, 2021, 79, 446-452.	0.9	24
155	Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. Journal of Urology, 2020, 204, 466-475.	0.2	24
156	Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29â€¯MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. Contemporary Clinical Trials, 2022, 112, 106618.	0.8	24
157	Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clinical Biochemistry, 2002, 35, 471-475.	0.8	23
158	Ageâ€related properties of the tumour vasculature in renal cell carcinoma. BJU International, 2011, 107, 416-424.	1.3	23
159	Active Surveillance for Prostate Cancer: How to Do It Right. Oncology, 2017, 31, 333-40, 345.	0.4	23
160	Early Prostate Cancer â€" Treat or Watch?. New England Journal of Medicine, 2011, 365, 568-569.	13.9	22
161	A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells. Biochemical and Biophysical Research Communications, 2015, 464, 848-854.	1.0	22
162	Overtreatment in cancer â€“ is it a problem?. Expert Opinion on Pharmacotherapy, 2016, 17, 1-5.	0.9	22

#	Article	IF	Citations
163	Impact of COVID-19 on medical education: introducing homo digitalis. World Journal of Urology, 2021, 39, 1997-2003.	1.2	22
164	Active surveillance and focal therapy for low-intermediate risk prostate cancer. Translational Andrology and Urology, 2015, 4, 342-54.	0.6	22
165	Active Surveillance: The Canadian Experience With an "Inclusive Approach". Journal of the National Cancer Institute Monographs, 2012, 2012, 234-241.	0.9	21
166	Testosterone therapy and prostate cancerâ€"safety concerns are well founded. Nature Reviews Urology, 2015, 12, 48-54.	1.9	21
167	Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 297.e9-297.e17.	0.8	21
168	The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 253-262.	1.4	21
169	Upper limit of cancer extent on biopsy defining very lowâ€risk prostate cancer. BJU International, 2015, 116, 213-219.	1.3	20
170	Contemporary Active Surveillance. Urologic Clinics of North America, 2017, 44, 565-574.	0.8	20
171	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 16.	0.3	20
172	Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines. European Urology Focus, 2020, 6, 1104-1110.	1.6	20
173	Expectant management with selective delayed intervention for favorable risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 175-179.	0.8	19
174	Prostate cancer immunology â€“ an update for Urologists. BJU International, 2011, 107, 1046-1051.	1.3	19
175	Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocolâ€based active surveillance: results from a contemporary European patient cohort. BJU International, 2012, 110, 195-200.	1.3	19
176	Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World Journal of Urology, 2015, 33, 907-916.	1.2	19
177	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	0.9	18
178	Novel approaches to improve prostate cancer diagnosis and management in earlyâ€stage disease. BJU International, 2012, 109, 1-7.	1.3	17
179	The uptake of active surveillance for the management of prostate cancer: A population-based analysis. Canadian Urological Association Journal, 2016, 10, 333.	0.3	17
180	Results of a survey of Canadian men with prostate cancer. Canadian Journal of Urology, 1997, 4, 359-365.	0.0	17

#	Article	IF	Citations
181	Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors. Urology, 2002, 59, 551-554.	0.5	16
182	Combined Androgen Blockade: An Update. Urologic Clinics of North America, 2006, 33, 161-166.	0.8	16
183	Maximal Testosterone Suppression in Prostate Cancerâ€"Free vs Total Testosterone. Urology, 2014, 83, 1217-1222.	0.5	16
184	New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men. European Urology, 2016, 69, 933-941.	0.9	16
185	Testosterone suppression in the treatment of recurrent or metastatic prostate cancer â€" A Canadian consensus statement. Canadian Urological Association Journal, 2017, 12, 30-7.	0.3	16
186	Impact of COVID-19 on Urology Practice: A Global Perspective and Snapshot Analysis. Journal of Clinical Medicine, 2020, 9, 1730.	1.0	16
187	Effect of ¹⁸F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology, 2022, 303, 414-422.	3.6	16
188	Intermittent Versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer. Current Urology Reports, 2013, 14, 159-167.	1.0	15
189	Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1795-1802.	1.5	15
190	Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials. Therapeutic Advances in Urology, 2016, 8, 75-82.	0.9	15
191	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	1.3	15
192	Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. Journal of Urology, 2019, 201, 721-727.	0.2	15
193	PREDICTORS OF PATHOLOGICAL STAGE BEFORE NEOADJUVANT ANDROGEN WITHDRAWAL THERAPY AND RADICAL PROSTATECTOMY. Journal of Urology, 1998, 159, 925-928.	0.2	14
194	Statin Clinical Trial (REALITY) for Prostate Cancer: an Over 15-Year Wait is Finally Over Thanks to a Dietary Supplement. Urologic Clinics of North America, 2011, 38, 325-331.	0.8	14
195	The Effects of Serum from Prostate Cancer Patients with Elevated Body Mass Index on Prostate Cancer Cells in Vitro. Lipid Insights, 2015, 8, LPI.S23135.	1.0	14
196	Defining â€˜progressionâ€™ and triggers for curative intervention during active surveillance. Current Opinion in Urology, 2015, 25, 258-266.	0.9	14
197	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. BMJ Open, 2017, 7, e017863.	0.8	14
198	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	0.6	14

#	Article	IF	Citations
199	Overdiagnosis in urologic cancer. World Journal of Urology, 2022, 40, 1-8.	1.2	14
200	Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer. Journal of Urology, 2020, 204, 934-940.	0.2	14
201	Restoring sexual function in prostate cancer patients: an innovative approach. Canadian Journal of Urology, 2004, 11, 2285-9.	0.0	14
202	Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis. Canadian Journal of Urology, 2006, 13 Suppl 1, 48-55.	0.0	14
203	Advances in nerve sparing for radical prostatectomy. Urology, 1999, 54, 956-959.	0.5	13
204	Variation in patterns of practice in diagnosing screen-detected prostate cancer. BJU International, 2004, 94, 1239-1244.	1.3	13
205	Current role of prostate-specific antigen kinetics in managing patients with prostate cancer. BJU International, 2006, 97, 451-455.	1.3	13
206	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. Clinical Cancer Research, 2018, 24, 5305-5312.	3.2	13
207	Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. Canadian Urological Association Journal, 2020, 15, 181-186.	0.3	13
208	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.2	13
209	Active Surveillance with Selective Delayed Intervention for Favourable Risk Prostate Cancer: Clinical Experience and a â€œNumber Needed to Treatâ€•Analysis. European Urology Supplements, 2006, 5, 479-486.	0.1	12
210	Results of Unilateral Genitofemoral Nerve Grafts with Contralateral Nerve Sparing During Radical Prostatectomy. Urology, 2007, 69, 1161-1164.	0.5	12
211	Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review. Korean Journal of Urology, 2010, 51, 665.	1.2	12
212	PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice. Canadian Urological Association Journal, 2007, 1, 17-21.	0.3	12
213	Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. Canadian Journal of Urology, 1996, 3, 246-250.	0.0	12
214	The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate. Prostate, 2008, 68, 345-353.	1.2	11
215	What is the best approach for screen-detected low volume cancers?â€”The case for observation. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 495-499.	0.8	11
216	Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer. European Urology, 2012, 61, 851-854.	0.9	11

#	Article	IF	Citations
217	Intermittent Androgen Deprivation Therapyâ€"An Important Treatment Option for Prostate Cancer. JAMA Oncology, 2016, 2, 1531.	3.4	11
218	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. European Urology, 2017, 71, 274-280.	0.9	11
219	A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA â€˜grey zoneâ€™. World Journal of Urology, 2018, 36, 341-348.	1.2	11
220	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. Canadian Urological Association Journal, 2020, 14, E453-E457.	0.3	11
221	Active Surveillance with Selective Delayed Intervention: A Biologically Nuanced Approach to Favorable-Risk Prostate Cancer. Clinical Prostate Cancer, 2003, 2, 106-110.	2.1	10
222	How (not) to communicate new scientific information: a memoir of the famous brindley lecture. BJU International, 2005, 96, 956-957.	1.3	10
223	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 781.e17-781.e24.	0.8	10
224	Active surveillance for low-risk prostate cancer. F1000 Medicine Reports, 2012, 4, 16.	2.9	10
225	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.0	10
226	Active surveillance for prostate cancer: a review. Archivos Espanoles De Urologia, 2011, 64, 806-14.	0.1	10
227	Review: Prostate capsule sparing radical cystectomy: oncologic safety and clinical outcome. Therapeutic Advances in Urology, 2009, 1, 43-50.	0.9	9
228	Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial. Canadian Urological Association Journal, 2014, 8, 789.	0.3	9
229	Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise. BJU International, 2014, 113, E82-E89.	1.3	9
230	A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. Journal of Urology, 2018, 200, 335-343.	0.2	9
231	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer, 2020, 126, 583-592.	2.0	9
232	Active surveillance for good risk prostate cancer: rationale, method, and results. Canadian Journal of Urology, 2005, 12 Suppl 2, 21-4.	0.0	9
233	Cardiovascular effects of androgen depletion and replacement therapy. Urology, 2006, 67, 1126-1132.	0.5	8
234	Exercise Does Not Counteract the Effects of a â€œWesternizedâ€•Diet on Prostate Cancer Xenografts. Prostate, 2013, 73, 1223-1232.	1.2	8

#	Article	IF	Citations
235	The future of active surveillance. Translational Andrology and Urology, 2018, 7, 256-259.	0.6	8
236	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. International Journal of Radiation Oncology Biology Physics, 2019, 104, 61-66.	0.4	8
237	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	2.6	8
238	Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model. Anticancer Research, 2019, 39, 113-118.	0.5	8
239	Patientsâ€™ perspective of telephone visits during the COVID-19 pandemic. Canadian Urological Association Journal, 2020, 14, E402-E406.	0.3	8
240	Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. Journal of Urology, 2020, 203, 940-948.	0.2	8
241	Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. Journal of Urology, 2020, 204, 416-426.	0.2	8
242	Post transurethral resection of prostate incontinence in previously radiated prostate cancer patients. Canadian Journal of Urology, 1998, 5, 560-563.	0.0	8
243	The Continuing Role of PSA in the Detection and Management of Prostate Cancer. European Urology Supplements, 2007, 6, 327-333.	0.1	7
244	Emerging drugs for prostate cancer. Expert Opinion on Emerging Drugs, 2009, 14, 455-470.	1.0	7
245	Canadian Consensus Conference: The FDA decision on the use of 5ARIs. Canadian Urological Association Journal, 2012, 6, 83-88.	0.3	7
246	Active Surveillance for Prostate Cancer: Debate over the Application, Not the Concept. European Urology, 2015, 67, 1006-1008.	0.9	7
247	Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance. Prostate Cancer and Prostatic Diseases, 2018, 21, 187-195.	2.0	7
248	When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy. Canadian Urological Association Journal, 2020, 15, 115-121.	0.3	7
249	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 929.e1-929.e10.	0.8	7
250	The history of intermittent androgen- deprivation therapy â€" A Canadian story. Canadian Urological Association Journal, 2020, 14, 159-162.	0.3	7
251	Current evidence for focal therapy and partial gland ablation for organ-confined prostate cancer: systematic review of literature published in the last 2 years. Current Opinion in Urology, 2021, 31, 49-57.	0.9	7
252	Influence of Sociodemographic Factors on Definitive Intervention Among Low-risk Active Surveillance Patients. Urology, 2021, 155, 117-123.	0.5	7

#	Article	IF	Citations
253	Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. Oncology, 2014, 28, 950-C3.	0.4	7
254	RE: EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER. Journal of Urology, 2000, 164, 1666-1666.	0.2	6
255	Back to nephrectomy for patients with metastatic renal cancer. Lancet, The, 2001, 358, 948-949.	6.3	6
256	Current Role of PSA Kinetics in the Management of Patients with Prostate Cancer. European Urology Supplements, 2006, 5, 472-478.	0.1	6
257	Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression. Journal of Urology, 2016, 196, 986-988.	0.2	6
258	Systematic review and meta-analysis of trials evaluating the role of adjuvant radiation after radical prostatectomy for prostate cancer: Implications for early salvage. Canadian Urological Association Journal, 2020, 14, 330-336.	0.3	6
259	Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion) Tj ETQq1 1 0.784314 rgBT /Ov	1.2	6
260	Incidental Prostate Cancer (cT1aâ€“cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. European Urology Oncology, 2021, , .	2.6	6
261	Adding prostate-specific membrane antigen positron emission tomography (PSMA PET) to our prostate cancer armamentarium raises many questions. Canadian Urological Association Journal, 2020, 15, 179-80.	0.3	6
262	Re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of â€œManelsâ€•in Major Urology Meetings. Eur Urol 2021;80:442â€“9. European Urology, 2021, 80, e100.	0.9	6
263	The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.. Journal of Clinical Oncology, 2020, 38, 364-364.	0.8	6
264	Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections, 2019, 8, 132-140.	0.8	6
265	Practice patterns of Canadian urologists in the management of stage I testicular seminoma. Canadian Journal of Urology, 2004, 11, 2194-9.	0.0	6
266	Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?. Seminars in Oncology, 2003, 30, 587-595.	0.8	5
267	Advanced Prostate Cancer: Hormones and Beyond. European Urology Supplements, 2007, 6, 354-364.	0.1	5
268	1293 PREVIOUSLY DEVELOPED SYSTEMS-BASED BIOPSY MODEL (PROSTATE PX+) IDENTIFIES FAVORABLE-RISK PROSTATE CANCER FOR MEN ENROLLED IN AN ACTIVE SURVEILLANCE PROGRAM. Journal of Urology, 2011, 185, .	0.2	5
269	Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. Canadian Urological Association Journal, 2013, 7, 450.	0.3	5
270	Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer. Journal of Urology, 2021, 206, 1166-1176.	0.2	5

#	Article	IF	Citations
271	Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice. Canadian Urological Association Journal, 2021, 16, .	0.3	5
272	What Can Surrogate Tissues Tell Us about the Oxidative Stress Status of the Prostate? A Hypothesis-Generating In-Vivo Study. PLoS ONE, 2010, 5, e15880.	1.1	5
273	Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells. Anticancer Research, 2017, 37, 6601-6607.	0.5	5
274	Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease. Canadian Journal of Urology, 2005, 12 Suppl 1, 53-7; discussion 101-2.	0.0	5
275	PSA recurrence: definitions, PSA kinetics, and identifying patients at risk. Canadian Journal of Urology, 2006, 13 Suppl 2, 43-7.	0.0	5
276	Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. European Urology Open Science, 2022, 41, 126-133.	0.2	5
277	Localised and Locally Advanced Prostate Cancer: Who to Treat and How?. European Urology Supplements, 2007, 6, 334-343.	0.1	4
278	Active surveillance for favorable-risk prostate cancer: What are the results and how safe is it?. Current Urology Reports, 2007, 8, 341-344.	1.0	4
279	Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy. Nature Reviews Urology, 2008, 5, 362-363.	1.4	4
280	Strengthening evidence for active surveillance for prostate cancer. European Urology, 2013, 63, 108-110.	0.9	4
281	Improving quality of care. Canadian Urological Association Journal, 2013, 4, 299.	0.3	4
282	The case for prostate capsule-sparing radical cystectomy in selected patients. Canadian Urological Association Journal, 2013, 3, 215.	0.3	4
283	Practice patterns of post-radical prostatectomy incontinence surgery in Ontario. Canadian Urological Association Journal, 2014, 8, 670.	0.3	4
284	Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists.. Journal of Clinical Oncology, 2013, 31, 42-42.	0.8	4
285	Active Surveillance for Favorable-Risk Prostate Cancer. , 2013, , 621-629.		4
286	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	0.9	4
287	Point: Active Surveillance for Favorable Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 693-698.	2.3	3
288	Dietary Agents for Prostate Cancer Chemoprevention: An Overview. Current Cancer Therapy Reviews, 2010, 6, 308-316.	0.2	3

#	Article	IF	Citations
289	Intermittent Androgen Deprivation Therapy: Clarity from Confusion. European Urology, 2013, 64, 731-733.	0.9	3
290	Active surveillance. Current Opinion in Urology, 2013, 23, 237-238.	0.9	3
291	Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. Canadian Urological Association Journal, 2013, 3, 460.	0.3	3
292	Crossâ€continental comparison of safety and protection measures amongst urologists during COVIDâ€19. International Journal of Urology, 2020, 27, 981-989.	0.5	3
293	Scoping review: hotspots for COVID-19 urological research: what is being published and from where?. World Journal of Urology, 2020, 39, 3151-3160.	1.2	3
294	Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. European Urology Focus, 2021, , .	1.6	3
295	Selling ourselves short. Canadian Journal of Urology, 2003, 10, 1969.	0.0	3
296	Spontaneous rupture of renal cell carcinoma associated with acute pancreatitis. Urology, 1993, 42, 445-446.	0.5	2
297	Re: Effect of Dutasteride on the Risk of Prostate Cancer. European Urology, 2010, 58, 313.	0.9	2
298	Feasibility and Safety of Silicone Rubber Contrast-Enhanced Microcomputed Tomography in Evaluating the Angioarchitecture of Prostatectomy Specimens. Translational Oncology, 2011, 4, 173-177.	1.7	2
299	Does screening for prostate cancer reduce prostate cancer mortality?. Canadian Urological Association Journal, 2013, 3, 187.	0.3	2
300	Management of low- and intermediate-risk prostate cancer. World Journal of Urology, 2015, 33, 905-906.	1.2	2
301	Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer. Journal of Urology, 2016, 196, 309-311.	0.2	2
302	The drama of prostate cancer diagnostics. Lancet Oncology, The, 2017, 18, e132.	5.1	2
303	What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?. Canadian Urological Association Journal, 2017, 11, 118.	0.3	2
304	Prostate cancer prevention: proof is elusive. BJU International, 2018, 121, 487-488.	1.3	2
305	Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urology, 2018, 18, 77.	0.6	2
306	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database. Canadian Urological Association Journal, 2019, 14, 24-30.	0.3	2

#	Article	IF	Citations
307	Outreach and Influence of Surgical Societiesâ€™ Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemicâ€"An Anonymized International Urologic Expert Inquiry. Urology, 2020, 145, 73-78.	0.5	2
308	Active Surveillance: The Canadian Experience. , 2012, , 95-105.		2
309	Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up.. Journal of Clinical Oncology, 2013, 31, 1-1.	0.8	2
310	Gleason grading controversies: what the chemoprevention trials have taught us. Canadian Urological Association Journal, 2013, 3, 115.	0.3	2
311	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.. Journal of Clinical Oncology, 2020, 38, 131-131.	0.8	2
312	Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-NaÃ¯ve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy. Journal of Urology, 2022, , 101097JU0000000000002384.	0.2	2
313	A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided biopsy in the detection of prOstate cancer. PLoS ONE, 2022, 17, e0263345.	1.1	2
314	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	1.2	2
315	Degarelix acetate for the treatment of prostate cancer. Drugs of Today, 2009, 45, 725-30.	0.7	2
316	Outcomes of Treatment vs Observation of Localized Prostate Cancer in Elderly Men. JAMA - Journal of the American Medical Association, 2007, 297, 1651.	3.8	1
317	Re: Cumulative Association of Five Genetic Variants with Prostate Cancer. European Urology, 2008, 53, 1298-1299.	0.9	1
318	Active Surveillance for Favorable Risk Prostate Cancer. Journal of Urology, 2009, 182, 2565-2566.	0.2	1
319	Reply to P.B. Singh et al. Journal of Clinical Oncology, 2010, 28, e514-e514.	0.8	1
320	The decline and fall of RCTs. Canadian Urological Association Journal, 2011, 5, 229-229.	0.3	1
321	CUAJ implements early releases. Canadian Urological Association Journal, 2011, 5, 7-7.	0.3	1
322	Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists. Canadian Urological Association Journal, 2012, 1, S69-70.	0.3	1
323	Still unconvinced on the use of salvage prostatectomy. Canadian Urological Association Journal, 2013, 7, 93.	0.3	1
324	The importance of feedback. Canadian Urological Association Journal, 2013, 3, 9.	0.3	1

#	Article	IF	Citations
325	Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. Canadian Urological Association Journal, 2017, 12, E59-63.	0.3	1
326	Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer. New England Journal of Medicine, 2019, 381, 84-86.	13.9	1
327	Re: Prostate Cancer-specific Mortality Across Gleason Scores in Black vs Nonblack Men. European Urology, 2019, 75, 1036-1037.	0.9	1
328	Letter â€“ Can micro-ultrasound be the new first-choice test for patients with a suspicion of prostate cancer?. Canadian Urological Association Journal, 2020, 15, E127-8.	0.3	1
329	The â€˜Câ€™ Words: parallels and analogies between Prostate Cancer and Covid-19. World Journal of Urology, 2021, 39, 3175-3176.	1.2	1
330	Reply by Authors. Journal of Urology, 2021, 205, 779-779.	0.2	1
331	Active Surveillance for Low Risk Prostate Cancer. , 2017, , 161-170.		1
332	Analysis of small non-coding RNAs in urinary exosomes to classify prostate cancer into low-grade (GG1) and higher-grade (GG2-5).. Journal of Clinical Oncology, 2020, 38, 277-277.	0.8	1
333	USPSTF and FDA: PSA and 5ARIs. Canadian Urological Association Journal, 2011, 5, 373-374.	0.3	1
334	Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study.. Journal of Clinical Oncology, 2012, 30, 30-30.	0.8	1
335	Impact of compliance on outcomes for patients on active surveillance for prostate cancer.. Journal of Clinical Oncology, 2019, 37, 36-36.	0.8	1
336	Active surveillance for low-risk prostate cancer â€“ in pursuit of a standardized protocol. Central European Journal of Urology, 2020, 73, 123-126.	0.2	1
337	International regional working groups on prostate cancer: results of consensus development. Canadian Journal of Urology, 2005, 12 Suppl 1, 86-91.	0.0	1
338	Active surveillance not only reduces morbidity, It saves lives. Oncology, 2013, 27, 522, 593.	0.4	1
339	Active surveillance in intermediate risk prostate cancer. Archivos Espanoles De Urologia, 2019, 72, 157-166.	0.1	1
340	Reactions. Lancet, The, 2002, 360, 1869.	6.3	0
341	A new journal and new opportunities. Canadian Urological Association Journal, 2007, 1, 9.	0.3	0
342	Un nouveau journal et de nouvelles possibilitÃ©s. Canadian Urological Association Journal, 2007, 1, 11.	0.3	0

#	Article	IF	Citations
343	Reply to F. Campodonico et al. Journal of Clinical Oncology, 2010, 28, e212-e212.	0.8	0
344	Reply to J.B. Aragon-Ching. Journal of Clinical Oncology, 2010, 28, e267-e267.	0.8	0
345	Publishing in Urology: My 20-year journey. Canadian Urological Association Journal, 2012, 6, 223-223.	0.3	0
346	How (not) to communicate new scientific information: a memoir of the famous Brindley lecture. Trends in Urology & Men's Health, 2012, 3, 35-36.	0.2	0
347	The uses of error. Canadian Urological Association Journal, 2012, 1, 235.	0.3	0
348	Meeting your high expectations. Canadian Urological Association Journal, 2013, 2, 595.	0.3	0
349	Health advocacy in urology training. Canadian Urological Association Journal, 2013, 1, 356.	0.3	0
350	Un plaidoyer pour la santÃ© dans la formation en urologie. Canadian Urological Association Journal, 2013, 1, 357.	0.3	0
351	CUA: making Canada proud at the AUA. Canadian Urological Association Journal, 2013, 3, 185.	0.3	0
352	IndexÃ© !!!. Canadian Urological Association Journal, 2013, 2, 91.	0.3	0
353	Indexation: not quite yet. Canadian Urological Association Journal, 2013, 2, 169.	0.3	0
354	The improved CUA Office of Education. Canadian Urological Association Journal, 2013, 2, 491.	0.3	0
355	An unsung Canadian hero!. Canadian Urological Association Journal, 2013, 4, 371.	0.3	0
356	The editor is back. Canadian Urological Association Journal, 2013, 3, 277.	0.3	0
357	EBM in Canadian urology. Canadian Urological Association Journal, 2013, 4, 83.	0.3	0
358	The impact of surgical complexities. Canadian Urological Association Journal, 2013, 2, 9.	0.3	0
359	The bright future of the CUA. Canadian Urological Association Journal, 2013, 2, 365.	0.3	0
360	Prostate cancer screening: Canadian guidelines 2011. Canadian Urological Association Journal, 2013, 5, 235.	0.3	0

#	Article	IF	Citations
361	Conservative management for low-risk prostate cancer improves quality-adjusted lifeÂexpectancy at lower cost compared with initial treatment. Evidence-Based Medicine, 2014, 19, 40-40.	0.6	0
362	Reply by the Authors. Urology, 2014, 84, 1250-1251.	0.5	0
363	Editorial Comment. Urology, 2015, 86, 996.	0.5	0
364	Active Surveillance: Rationale, Patient Selection, Follow-up, and Outcomes. , 2016, , 215-223.		0
365	Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 62.	0.3	0
366	Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer. JAMA Oncology, 2018, 4, 1133.	3.4	0
367	Age-Related Mental Health Consequences of COVID-19: A Global Perspective. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, 25-31.	0.2	0
368	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press. European Urology Oncology, 2021, 5, 261-261.	2.6	0
369	Not So â€œActiveâ€•Surveillance. International Journal of Radiation Oncology Biology Physics, 2021, 110, 716-717.	0.4	0
370	Reply by Authors. Journal of Urology, 2021, 206, 1176.	0.2	0
371	Outcomes of 200 Patients with Localized Prostate Cancer Enrolled in a Watchful Waiting Protocol. UroOncology, 2002, 2, 93-94.	0.1	0
372	JAUC met en oeuvre les â€œsorties prÃ©maturÃ©esâ€• Canadian Urological Association Journal, 2011, 5, 9-9.	0.3	0
373	Le dÃ©clin et la chute des ECR. Canadian Urological Association Journal, 2011, 5, 231-231.	0.3	0
374	Lâ€™USPSTF et la FDA: Lâ€™APS et les I5AR. Canadian Urological Association Journal, 2011, 5, 375-376.	0.3	0
375	Active Surveillance Comes of Age. , 2012, , 215-223.		0
376	Active Surveillance for Favorable Risk Prostate Cancer: Background, Patient Selection, Triggers for Intervention, and Outcomes. , 2012, , 85-91.		0
377	Role of 5-alpha-reductase inhibitors in active surveillance of patients with low-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 14-14.	0.8	0
378	Tout est dans lâ€™emplacement : des biopsies prostatiques et de lâ€™IRM. Canadian Urological Association Journal, 2012, 6, 81-81.	0.3	0

#	Article	IF	Citations
379	Highâ€dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. FASEB Journal, 2012, 26, 388.5.	0.2	0
380	Current Status of Clinical Trials in Active Surveillance. , 2016, , 141-152.		0
381	Efficacy and safety of enzalutamide vs bicalutamide in European and North American men participating in the TERRAIN trial.. Journal of Clinical Oncology, 2016, 34, 5063-5063.	0.8	0
382	Low-Risk Prostate Cancer in North America: Rationale, Uptake, and Limitations of Active Surveillance and Opportunities for Focal Therapy. Current Clinical Urology, 2017, , 51-56.	0.0	0
383	A phase I pilot study of preoperative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.. Journal of Clinical Oncology, 2019, 37, 60-60.	0.8	0
384	Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.. Journal of Clinical Oncology, 2020, 38, 221-221.	0.8	0
385	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.2	0
386	Comparison of micro-ultrasound and multiparametric MRI imaging for prostate cancer: A multicenter prospective analysis.. Journal of Clinical Oncology, 2020, 38, 296-296.	0.8	0
387	Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy.. Journal of Clinical Oncology, 2020, 38, 148-148.	0.8	0
388	L'effet des complexitÃ©s chirurgicales. Canadian Urological Association Journal, 2008, 2, 11.	0.3	0
389	Using consensus guidelines effectively. Canadian Urological Association Journal, 2010, 4, 7-8.	0.3	0
390	Reply by Authors. Journal of Urology, 2020, 204, 475-475.	0.2	0
391	"An individual's sexuality reflects the depths of their soul." Nietchse. Canadian Journal of Urology, 1999, 6, 718.	0.0	0
392	Office based drug trials. Canadian Journal of Urology, 1999, 6, 826.	0.0	0
393	"I never go to bed with a girl on the first date, but that's more of a guideline than a rule". Canadian Journal of Urology, 1998, 5, 460.	0.0	0
394	Bacille Calmette-Guerin (BCG) associated epididymitis: a case report and review. Canadian Journal of Urology, 1998, 5, 477-481.	0.0	0
395	The future of urologic research in Canada:. Canadian Journal of Urology, 1998, 5, 576.	0.0	0
396	Editorial 1240 1240 Laurence H. Klotz EDITORIAL. Canadian Journal of Urology, 2001, 8, 1240.	0.0	0

#	Article	IF	Citations
397	Gender assignment and ideology. Canadian Journal of Urology, 2002, 9, 1442.	0.0	0
398	Guidelines and trials. Canadian Journal of Urology, 2002, 9, 1623.	0.0	0
399	Romanow, Romanow, wherefore art thou Romanow?. Canadian Journal of Urology, 2002, 9, 1672.	0.0	0
400	EDITORIAL. Canadian Journal of Urology, 1997, 4, 431.	0.0	0
401	EDITORIAL. Canadian Journal of Urology, 1997, 4, 392.	0.0	0
402	Can radiotherapy salvage isolated local recurrence following radical prostatectomy?. Canadian Journal of Urology, 1997, 4, 395-399.	0.0	0
403	EDITORIAL. Canadian Journal of Urology, 1997, 4, 314.	0.0	0
404	Survey of consecutive prostate cancer patients attending the Toronto Sunnybrook Regional Cancer Centre (TSRCC). Canadian Journal of Urology, 1996, 3, 268-276.	0.0	0
405	EDITORIAL. Canadian Journal of Urology, 1996, 3, A7.	0.0	0
406	EDITORIAL. Canadian Journal of Urology, 1996, 3, A9.	0.0	0
407	EDITORIAL. Canadian Journal of Urology, 1996, 3, A7.	0.0	0
408	EDITORIAL. Canadian Journal of Urology, 1996, 3, A5.	0.0	0
409	Endo urology and uro oncology. Canadian Journal of Urology, 2004, 11, 2108.	0.0	0
410	Geopolitics and the CJU. Canadian Journal of Urology, 2004, 11, 2169-70.	0.0	0
411	'Gammon's law and a change in thinking?'. Canadian Journal of Urology, 2004, 11, 2226.	0.0	0
412	Industry sponsored research. Canadian Journal of Urology, 2004, 11, 2312-3.	0.0	0
413	Live donor nephrectomy. Canadian Journal of Urology, 2005, 12, 2506.	0.0	0
414	Impact of the Chaouli decision. Canadian Journal of Urology, 2005, 12, 2726.	0.0	0

#	Article	IF	Citations
415	Seeing is believing: image guided therapy in urology. Canadian Journal of Urology, 2005, 12, 2870.	0.0	0
416	Out of country health care. Canadian Journal of Urology, 2006, 13, 2947.	0.0	0
417	Androgen replacement and/or 5 alpha reductase inhibitors in aging men. Canadian Journal of Urology, 2006, 13 Suppl 1, 44-5.	0.0	0
418	Focal therapy: definition and rationale. Current Opinion in Urology, 2022, 32, 218-223.	0.9	0